{"id":7217,"date":"2005-07-14T08:44:23","date_gmt":"2005-07-14T07:44:23","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=7217"},"modified":"2014-05-21T17:25:40","modified_gmt":"2014-05-21T17:25:40","slug":"tipranavir-aptivus-approved-in-us","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/7217","title":{"rendered":"Tipranavir (Aptivus) approved in US"},"content":{"rendered":"<p><strong>On June 22, 2005, the US Food and Drug Administration (FDA) granted accelerated approval of a new protease inhibor, tipranavir (Aptivus). Tipranavir, co-administered with 200 mg of ritonavir, is indicated for adult patients who are highly treatment-experienced or have HIV-1 strains resistant to multiple PIs.<\/strong><\/p>\n<p>The approval of tipranavir\/r is based on 24-week results from of two controlled phase III studies previously reported in HTB (RESIST 1 and 2). A statistically greater percentage of HIV-positive patients taking tipranavir\/r achieved treatment response versus the comparator group (40% vs 18%). Treatment response was defined as a confirmed 1 log or greater decrease in HIV RNA from baseline.<\/p>\n<p>The approved dose of tipranavir is 500 mg taken with 200 mg of ritonavir, twice daily with food. Taking the drug with food improves absorption.<\/p>\n<p>Source: FDA listlesrve and Boehringer Ingelheim PR<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On June 22, 2005, the US Food and Drug Administration (FDA) granted accelerated approval of a new protease inhibor, tipranavir (Aptivus). Tipranavir, co-administered with 200 mg of ritonavir, is indicated for adult patients who are highly treatment-experienced or have HIV-1 &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-7217","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/7217","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=7217"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/7217\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=7217"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=7217"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=7217"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}